The three-year-old spinout from Zimmer Biomet has reached the end of its road. | The three-year-old spinout from Zimmer ...

Concentra Biosciences is living up to its reputation of buying beleaguered biotechs, this time swooping in to grab iTeos ...

Medtronic has secured a new approval in Europe greatly expanding the reach of its MiniMed 780G pump system—including for ...

The Sarepta saga continues, with the FDA slapping a clinical hold across all of the company’s investigational limb girdle ...

Alkermes outlined plans to move its NT1 drug candidate, alixorexton, into phase 3 after posting results from the midstage ...

Roche’s hopes of getting its chronic obstructive pulmonary disease (COPD) drug astegolimab to regulators this year have taken ...

With its Poolbeg Pharma merger plans having bitten the dust and key assets sold off to Gilead, Hookipa Pharma has decided ...

Berkeley is getting a boost, launching a dedicated space for expanding companies that have outgrown their starter homes. | A biotech incubator at the University of California, Berkeley is getting a ...

Omega Funds has raised $647 million for the investment shop’s latest round aimed at life sciences companies targeting unmet medical needs. | Omega Funds has raised $647 million for the investment shop ...

Sail Biomedicines is shrinking its crew for the second time this year. | Sail Biomedicines is shrinking its crew for the ...

Kennedy Jr. has downplayed the effectiveness of the long-used vaccine and instead promoted the development of new treatments ...

On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.